Clinical Trial Update: Efficacy and Safety of SAR292833 Administration for 4 Weeks in Patients With Chronic Peripheral Neuropathic Pain [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating the efficacy and safety of SAR292833 given for 4 weeks in patients with chronic peripheral neuropathic pain.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuropathic Pain

Drugs mentioned

• SAR292833

Snippet

Sponsor: Sanofi | Conditions: Neuropathic Pain | Phase 2 | Status: COMPLETED